134 related articles for article (PubMed ID: 12019915)
1. Cost-effectiveness analysis of the russian treatment scheme for tuberculosis versus short-course chemotherapy: results from Tomsk, Siberia.
Jacobs B; Clowes C; Wares F; Polivakho V; Lyagoshina T; Peremitin G; Banatvala N
Int J Tuberc Lung Dis; 2002 May; 6(5):396-405. PubMed ID: 12019915
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of different treatment strategies for tuberculosis in Egypt and Syria.
Vassall A; Bagdadi S; Bashour H; Zaher H; Maaren PV
Int J Tuberc Lung Dis; 2002 Dec; 6(12):1083-90. PubMed ID: 12546116
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of tuberculosis control policies in Ivanovo Oblast, Russian Federation. Ivanovo Tuberculosis Project Study Group.
Migliori GB; Khomenko AG; Punga VV; Ambrosetti M; Danilova I; Ribka LN; Grzemska M; Sawert H; Raviglione MC
Bull World Health Organ; 1998; 76(5):475-83. PubMed ID: 9868838
[TBL] [Abstract][Full Text] [Related]
4. Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia.
Floyd K; Hutubessy R; Kliiman K; Centis R; Khurieva N; Jakobowiak W; Danilovits M; Peremitin G; Keshavjee S; Migliori GB
Eur Respir J; 2012 Jul; 40(1):133-42. PubMed ID: 22362862
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of DOTS in urban Brazil.
Mohan CI; Bishai D; Cavalcante S; Chaisson RE
Int J Tuberc Lung Dis; 2007 Jan; 11(1):27-32. PubMed ID: 17217126
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of public-private mix for tuberculosis care and control, India. Part II. Cost and cost-effectiveness.
Pantoja A; Lönnroth K; Lal SS; Chauhan LS; Uplekar M; Padma MR; Unnikrishnan KP; Rajesh J; Kumar P; Sahu S; Wares F; Floyd K
Int J Tuberc Lung Dis; 2009 Jun; 13(6):705-12. PubMed ID: 19460245
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effectiveness of WHO short-course chemotherapy and standard Russian antituberculous regimens in Tomsk, western Siberia.
Mawer C; Ignatenko N; Wares D; Strelis A; Golubchikova V; Yanova G; Lyagoshina T; Sharaburova O; Banatvala N
Lancet; 2001 Aug; 358(9280):445-9. PubMed ID: 11513907
[TBL] [Abstract][Full Text] [Related]
8. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of an alternative tuberculosis management strategy for permanent farm dwellers in South Africa amidst health service contraction.
Clarke M; Dick J; Bogg L
Scand J Public Health; 2006; 34(1):83-91. PubMed ID: 16449048
[TBL] [Abstract][Full Text] [Related]
10. Cost comparison of wirelessly vs. directly observed therapy for adherence confirmation in anti-tuberculosis treatment.
Au-Yeung KY; DiCarlo L
Int J Tuberc Lung Dis; 2012 Nov; 16(11):1498-504. PubMed ID: 23006834
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis.
Gourevitch MN; Alcabes P; Wasserman WC; Arno PS
Int J Tuberc Lung Dis; 1998 Jul; 2(7):531-40. PubMed ID: 9661818
[TBL] [Abstract][Full Text] [Related]
12. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
Rothberg MB; Rose DN
Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
[TBL] [Abstract][Full Text] [Related]
13. Cost and cost-effectiveness of increased community and primary care facility involvement in tuberculosis care in Lilongwe District, Malawi.
Floyd K; Skeva J; Nyirenda T; Gausi F; Salaniponi F
Int J Tuberc Lung Dis; 2003 Sep; 7(9 Suppl 1):S29-37. PubMed ID: 12971652
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of public-private mix for tuberculosis care and control, India. Part I. Socio-economic profile and costs among tuberculosis patients.
Pantoja A; Floyd K; Unnikrishnan KP; Jitendra R; Padma MR; Lal SS; Uplekar M; Chauhan LS; Kumar P; Sahu S; Wares F; Lönnroth K
Int J Tuberc Lung Dis; 2009 Jun; 13(6):698-704. PubMed ID: 19460244
[TBL] [Abstract][Full Text] [Related]
15. Non-hospital DOT and early diagnosis of tuberculosis reduce costs while achieving treatment success.
Pichenda K; Nakamura K; Morita A; Kizuki M; Seino K; Takano T
Int J Tuberc Lung Dis; 2012 Jun; 16(6):828-34. PubMed ID: 22507700
[TBL] [Abstract][Full Text] [Related]
16. Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, in Ecuador.
Rouzier VA; Oxlade O; Verduga R; Gresely L; Menzies D
Int J Tuberc Lung Dis; 2010 Oct; 14(10):1316-22. PubMed ID: 20843424
[TBL] [Abstract][Full Text] [Related]
17. Costs and outcomes of tuberculosis control in the Russian Federation: retrospective cohort analysis.
Atun RA; Samyshkin Y; Drobniewski F; Balabanova Y; Fedorin I; Lord J; Coker RJ
Health Policy Plan; 2006 Sep; 21(5):353-64. PubMed ID: 16940301
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for defaulting from tuberculosis treatment: a prospective cohort study of 301 cases in the Gambia.
Hill PC; Stevens W; Hill S; Bah J; Donkor SA; Jallow A; Lienhardt C
Int J Tuberc Lung Dis; 2005 Dec; 9(12):1349-54. PubMed ID: 16466057
[TBL] [Abstract][Full Text] [Related]
19. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis.
Seung KJ; Gelmanova IE; Peremitin GG; Golubchikova VT; Pavlova VE; Sirotkina OB; Yanova GV; Strelis AK
Clin Infect Dis; 2004 Nov; 39(9):1321-8. PubMed ID: 15494909
[TBL] [Abstract][Full Text] [Related]
20. Anti-tuberculosis programs in Thailand: a cost analysis.
Chunhaswasdikul B; Kamolratanakul P; Jittinandana A; Tangcharoensathien V; Kuptawintu S; Pantumabamrung P
Southeast Asian J Trop Med Public Health; 1992 Jun; 23(2):195-9. PubMed ID: 1439970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
